Fierce Pharma
DECEMBER 20, 2024
Perhaps PD-1 inhibitors just arent for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
PM360
DECEMBER 20, 2024
Established in 2012, PM360 introduced the first-ever issue focused entirely on our industrys latest innovations. Categories explore every sector of the healthcare industry, from life sciences to marketing. PM360 would like to welcome you to the new age of innovation with our illuminating Innovations Issue. This yearly special issue has served as your go-to guide for the most interesting advancements in our industry over the past 13 years, by featuring a focussed view of 11 different areas in hea
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
DECEMBER 20, 2024
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove became the first innovative targeted lung cancer med developed by a Chinese company to win FDA approval. And more.
PM360
DECEMBER 20, 2024
In the high-stakes world of healthcare, the relationship between pharmaceutical advertising and the people it aims to reach is at a critical crossroads. For far too long, underserved communities have seen little in these ads that speak to their lives let alone their unique healthcare journeys. Now more than ever, the industry is recognizing that diversity, equity, and inclusion (DEI) are not just add-ons, but essential elements that define successful, meaningful campaigns.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
DECEMBER 20, 2024
Thanks to a new FDA green light, Lillys dual GIP/GLP-1 blockbuster Zepbound has become the first prescription medicine cleared to treat adults with moderate-to-severe obstructive sleep apnea and obesity. The nod marks the second indication for Zepbound behind the inaugural obesity approval it scored in November 2023.
Pharmaceutical Technology
DECEMBER 20, 2024
Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 20, 2024
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.
European Pharmaceutical Review
DECEMBER 20, 2024
Bristol Myers Squibb has licensed an amyloid-beta antibody programme from BioArctic AB. The PyroGlutamate-amyloid-beta (PyroGlu-A) programme includes novel antibodies (BAN1503 and BAN2803). These target a truncated, pyroglutamate modified form of amyloid-beta. BAN2803 utilises a technology platform that optimises biologic drug delivery past the blood brain barrier, BioArctic noted.
Pharmaceutical Technology
DECEMBER 20, 2024
Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
PharmaVoice
DECEMBER 20, 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 20, 2024
The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for reducing triglyceride levels in the adult population with FCS
Clarify Health
DECEMBER 20, 2024
Patient loyalty and satisfaction do more than enhance providers reputations and ratings: they can help encourage patients to stay with providers instead of seeking care elsewhere, a phenomenon known as patient leakage. Whether they choose a new provider on their own or are referred to one, losing patients can significantly impact providers revenue.
Pharmaceutical Technology
DECEMBER 20, 2024
Palleon and Henlius Biotech have entered into a licence agreement and partnership for the formers E-602 to treat autoimmune diseases.
MedCity News
DECEMBER 20, 2024
Vitalic provides mental health support to older adults. It connects them to a care team that includes geriatric boarded psychiatrists, psychiatric nurse practitioners, licensed therapists and mental health support coaches. The post Startup Launches to Provide Geriatric Behavioral Health Support appeared first on MedCity News.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
DECEMBER 20, 2024
The UK's DHSC has announced its anticipated 2025 headline payback rate for new medicines under the 20242028 VPAG.
PM360
DECEMBER 20, 2024
Stressful scenarios trigger the bodys fightor-flight responsecausing the heart to race, blood pressure to spike, and stress hormones to flood the system. Stress responses have a biological purpose but can also produce unintended consequences when triggered chronically. Research shows stresss negative long-term effects 1 on healthincluding the cardiovascular system.
Pharmaceutical Commerce
DECEMBER 20, 2024
Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the difference between return on invested capital in pharma compared to other organizations.
PM360
DECEMBER 20, 2024
Pilots are a go-to strategy of the pharmaceutical industry for getting new customer solutions into the marketplace. Most are still positioned at the periphery of the organizational operating model, with rigid definitions of success and failureminimizing their potential for lasting impact. As a result, there is a tendency to cut losses (and gains), moving quickly onto the next pilot.
PharmExec
DECEMBER 20, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
PM360
DECEMBER 20, 2024
After nearly five years of mounting pressures on the American healthcare system, providers and patients are confronting another challenge that shows no signs of slowing down: skyrocketing medical costs. Rising medical debt and high out-of-pocket expensesdriven in part by pharmaceutical price hikes, limited insurance coverage, shifts to high-deductible health plans, and the growing complexity of treatmentsplace an unprecedented burden on patients and providers.
Pharmaceutical Commerce
DECEMBER 20, 2024
In the fifth part of this roundtable discussion, subject matter experts discuss the role that various GS1 initiatives have played, and provide a breakdown of stakeholders who have benefitted greatly from RFID.
PM360
DECEMBER 20, 2024
The last several years have been a unique period for the life sciences industry globally, marked by both unprecedented innovation and financial volatility. While biopharma companies continue to unlock powerful new therapeutic discoveries, sluggish funding and other challenges have forced players throughout the sector to seek new strategies to maintain momentum.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Commerce
DECEMBER 20, 2024
As a result, the provider increases its involvement in the countrys pharma sector.
PM360
DECEMBER 20, 2024
Clinical trials can offer life saving treatments to patients in need. While most clinical trials fail to meet their intended endpoints, many succeed. However, not all people equally enjoy the opportunity to participate in clinical trials. Historically, racial and ethnic groups have been underrepresented in clinical trial studies. In 2020, the U.S. Food and Drug Administration reported that 75% of clinical trial subjects were white, while only 6% were Asian, 8% were Black, and 11% were Hispanic.
PharmaVoice
DECEMBER 20, 2024
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
PM360
DECEMBER 20, 2024
When the first biosimilars were approved by the FDA almost a decade ago, they were expected to provide a cost-effective alternative to expensive biologics, improve accessibility for patients and reduce healthcare spending by creating competition in the biologic market. But the benefits of biosimilars were not immediate, as early biologics had slower acceptance and savings than expected.
PharmaTech
DECEMBER 20, 2024
In this episode of Drug Digest, industry experts discuss their experiences in dealing with the challenges of developing and manufacturing next-generation biotherapeutics as well as triumphs that move the industry as a whole forward.
PM360
DECEMBER 20, 2024
DxCheck Launched in 2023, DxCheck is an AI-powered digital health platform that has swiftly emerged as a leader in personalized patient engagement across rare diseases, chronic conditions, and oncology. By leveraging advanced open-source language models and curated data, DxCheck delivers tailored resources and medically reviewed content that resonate with patients specific health needs.
PharmaTech
DECEMBER 20, 2024
The companies will use Orexos powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.
PM360
DECEMBER 20, 2024
Courier Health Powered by machine learning AI, Avalere Courier Health was founded in 2021 with the goal of revolutionizing the biopharma landscape with its groundbreaking patient-focused customer relationship management (CRM) platform. Designed specifically for Patient Services, Field Access, and Marketing, this proprietary platform addresses the challenges of coordinating and personalizing the patient journey for complex specialty medicinesa $400B market that accounted for 93% of FDA drug appro
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
186 
Let's personalize your content